0

Resiquimod

INQUIRY Add to cart
For Research Use Only | Not For Clinical Use
CATAP144875489
CAS144875-48-9
Structure
MDL NumberMFCD00937759
Molecular Weight314.38
InChI KeyBXNMTOQRYBFHNZ-UHFFFAOYSA-N
Description≥98% (HPLC)
SolubilityDMSO: 10 mg/mL, clear (warmed to 60 °C)
Assay≥98% (HPLC)
Colorwhite to tan
Formpowder; protect from light
Size10MG, 50MG
Storage Conditions−20°C
1

Actinic Keratosis - Review for Clinical Practice

Erika C V de Oliveira, Valéria R V da Motta, Paola C Pantoja, Carolina S de O Ilha, Renata F Magalhães, Hassan Galadari, Gislaine R Leonardi

Int J Dermatol. 2019 Apr;58(4):400-407.

PMID: 30070357

1

Co-delivery of Immunomodulators in Biodegradable Nanoparticles Improves Therapeutic Efficacy of Cancer Vaccines

C G Da Silva, M G M Camps, T M W Y Li, A B Chan, F Ossendorp, L J Cruz

Biomaterials. 2019 Nov;220:119417.

PMID: 31419588

1

Investigative Drugs for the Treatment of Cutaneous T-cell Lymphomas (CTCL): An Update

Egle Ramelyte, Reinhard Dummer, Emmanuella Guenova

Expert Opin Investig Drugs. 2019 Sep;28(9):799-809.

PMID: 31398295

1

Systemic Administration of a TLR7 Agonist Attenuates Regulatory T Cells by Dendritic Cell Modification and Overcomes Resistance to PD-L1 Blockade Therapy

Naoto Nishii, Hidetake Tachinami, Yuta Kondo, Yulong Xia, Yoshihisa Kashima, Tatsukuni Ohno, Shigenori Nagai, Lixin Li, Walter Lau, Hiroyuki Harada, Miyuki Azuma

Oncotarget. 2018 Jan 27;9(17):13301-13312.

PMID: 29568358

1

Tumor-secreted Pros1 Inhibits Macrophage M1 Polarization to Reduce Antitumor Immune Response

Eric Ubil, Laura Caskey, Alisha Holtzhausen, Debra Hunter, Charlotte Story, H Shelton Earp

J Clin Invest. 2018 Jun 1;128(6):2356-2369.

PMID: 29708510

  • Verification code
Contact Us

Send Us a Request

What is your specific need? We will do everything we can to meet your expectations.
Online Inquiry

Inquiry

For any inquiry, question or recommendation, please call: or fill out the following form.

  • Verification code

Head Office

  • Tel:
  • Email:

Follow us on

qrcode